Clinical Trials and Studies

MDA families eager for research breakthroughs take active roles to accelerate therapy development and spread awareness of MDA's mission

posted on July 14, 2015 - 3:19pm
Children and adults living with neuromuscular diseases are not only awaiting progress in the search for treatments and cures; they are directly supporting and advancing that progress in real and significant ways.

How unique advances are helping popularize the trend of accessible video gaming

posted on July 14, 2015 - 3:09pm
Quest Summer 2015
The World Health Organization estimates that at least 10 percent (roughly 700 million) of the world’s population is affected by a disability, while the Entertainment Software Association reports 500 million people play video games for at least an hour a day. The extent to which these two groups overlap on a global scale is unknown — but it’s likely more than you think.

Research and clinical trial updates

posted on July 14, 2015 - 3:03pm
Quest Summer 2015
Powerful Research MDA welcomes a neurological disease expert to the family

A look at symptoms, diagnosis, treatments and current MDA-supported research into this complex autoimmune disorder

posted on June 15, 2015 - 1:01pm
In recognition of June being National Myasthenia Gravis Awareness Month, MDA is examining the disease from several perspectives. This article offers an overview of signs, symptoms, diagnosis and treatments for myasthenia gravis (MG), as well as information on drugs that people with MG should avoid.

Progress in ALS research requires a free flow of information between MDA-supported laboratory investigators and leaders in the drug-development industry

posted on April 21, 2015 - 9:17am
Quest Spring 2015
ALS, also known as amyotrophic lateral sclerosis and Lou Gehrig’s disease, is among the most feared diseases facing people in the U.S. and worldwide. In ALS, the motor neurons — the nerve cells of the brain and spinal cord that control muscle action — mysteriously deteriorate, often within just a few years, leaving behind orphaned muscle fibers. Without signals from motor neurons, voluntary...

MDA's 2015 Scientific Conference points the way toward tomorrow's therapies

posted on April 21, 2015 - 9:07am
Quest Spring 2015
Last month, MDA brought together more than 400 of the nation’s leading scientists, researchers and professionals specializing in neuromuscular disease research and care at its 2015 Scientific Conference in Washington, D.C., March 11–14. This pre-eminent gathering, hosted every other year, was designed to accelerate discoveries and drug development for families fighting neuromuscular diseases.

Research and clinical trial updates

posted on April 21, 2015 - 9:03am
Quest Spring 2015
Research Leadership MDA welcomes two new muscle disease and ALS experts As part of MDA’s bold plan to accelerate treatments and cures for neuromuscular diseases, two new scientific program officers have joined the MDA family: Amanda Haidet-Phillips, Ph.D., and Laura Hagerty, Ph.D. Under the leadership of MDA Senior Vice President and Scientific Program Director Grace Pavlath, Ph.D., they will...

Santhera Pharmaceuticals is testing anti-cell death compound omigapil in children and teens with merosin-deficient and Ullrich congenital muscular dystrophies

posted on March 26, 2015 - 6:57pm
Santhera Pharmaceuticals continues to recruit participants for a phase 1 trial of omigapil in children and adolescents with the type 1A form of congenital muscular dystrophy (CMD)